Viyash Scientific Limited Intimates Demise of AVP – Legal and Compliance Mr. Phillip Trott

1 min read     Updated on 18 May 2026, 08:26 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Viyash Scientific Limited (formerly Sequent Scientific Limited), headquartered in Hyderabad, disclosed the demise of Mr. Phillip Trott, AVP – Legal and Compliance and a senior management member, on May 15, 2026. The regulatory filing was submitted to BSE and NSE on May 16, 2026, by Company Secretary Yoshita Vora, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

powered bylight_fuzz_icon
40496071

*this image is generated using AI for illustrative purposes only.

Viyash Scientific Limited (formerly known as Sequent Scientific Limited), headquartered at Jubilee Hills, Hyderabad, Telangana, has intimated the stock exchanges of the sad demise of Mr. Phillip Trott, AVP – Legal and Compliance, a member of the company's senior management. The event occurred on May 15, 2026, and the disclosure was filed with BSE Limited and the National Stock Exchange of India Limited on May 16, 2026, in accordance with applicable regulatory requirements.

Regulatory Disclosure

The intimation was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time. The filing was submitted by Yoshita Vora, Company Secretary and Compliance Officer of Viyash Scientific Limited.

Details of the Senior Management Change

The following details have been disclosed as part of Annexure A submitted to the exchanges:

Parameter: Details
Reason for Change: Demise of Mr. Phillip Trott, AVP – Legal and Compliance, a member of the senior management of the Company
Date of Cessation: May 15, 2026
Brief Profile (in case of appointment): Not Applicable
Disclosure of relationships between directors (in case of appointment of a director): Not Applicable

Viyash Scientific Limited expressed regret over the passing of Mr. Phillip Trott in its communication to the exchanges. The company is formerly known as Sequent Scientific Limited and operates with its registered office at the 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, Jubilee Hills, Hyderabad, Telangana.

Historical Stock Returns for Viyash Scientific

1 Day5 Days1 Month6 Months1 Year5 Years
-1.35%-3.87%+25.54%+26.09%+30.72%-9.18%

How will Viyash Scientific ensure continuity in its legal and compliance functions while searching for a replacement for the AVP – Legal and Compliance role?

Could the vacancy in the senior compliance leadership position impact Viyash Scientific's ability to meet upcoming regulatory deadlines or ongoing SEBI obligations?

What succession planning mechanisms does Viyash Scientific have in place to manage sudden senior management departures, particularly in critical compliance roles?

Viyash Scientific Limited to Host Q4FY26 Earnings Conference Call on May 20, 2026

1 min read     Updated on 12 May 2026, 12:28 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, has scheduled a Q4FY26 Earnings Conference Call with analysts and investors for May 20, 2026, at 4:00 PM IST. The call will be addressed by senior leadership including the Managing Director & Group CEO, Executive Director and CEO – Animal Health, and the Chief Financial Officer. The intimation was filed with BSE Limited and the National Stock Exchange of India Limited on May 12, 2026, in accordance with SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. Investors can dial in via +91 22 6280 1263 or +91 22 7115 8213 to participate in the call.

powered bylight_fuzz_icon
40114698

*this image is generated using AI for illustrative purposes only.

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, has announced a conference call with analysts and investors to discuss its Q4FY26 financial results. The call is scheduled for Wednesday, May 20, 2026, at 4:00 PM IST. The intimation was filed with BSE Limited and the National Stock Exchange of India Limited on May 12, 2026, in compliance with Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Details

The Q4FY26 Earnings Conference Call will bring together senior members of the company's leadership team to address analysts and investors. The following key details summarise the event:

Parameter: Details
Event: Q4 FY26 Earnings Conference Call
Date: Wednesday, May 20, 2026
Time: 4:00 PM IST
Universal Access Numbers: +91 22 6280 1263 / +91 22 7115 8213

Key Speakers

The conference call will feature participation from the following senior executives of Viyash Scientific Limited:

  • Dr. Hari Babu Bodepudi – Managing Director & Group CEO
  • Mr. Rajaram Narayanan – Executive Director and CEO – Animal Health
  • Mr. Ramakant Singani – Chief Financial Officer

Regulatory Compliance

The intimation was submitted by Yoshita Vora, Company Secretary & Compliance Officer of Viyash Scientific Limited, to both BSE Limited and the National Stock Exchange of India Limited on May 12, 2026. The filing was made pursuant to the applicable SEBI listing regulations. Further details regarding the conference call are also available on the company's website under the Investors Section at www.viyash.com .

Historical Stock Returns for Viyash Scientific

1 Day5 Days1 Month6 Months1 Year5 Years
-1.35%-3.87%+25.54%+26.09%+30.72%-9.18%

How has the rebranding from Sequent Scientific to Viyash Scientific impacted investor sentiment and the company's market positioning in the animal health pharmaceutical sector?

What revenue growth trajectory and margin expansion can investors expect from Viyash Scientific's animal health division in FY27 given the competitive landscape?

Will Viyash Scientific announce any strategic acquisitions, partnerships, or geographic expansions during the Q4FY26 earnings call to accelerate its global veterinary pharma footprint?

More News on Viyash Scientific

1 Year Returns:+30.72%